Global age-sex-specific all-cause mortality and life expectancy estimates for 204 countries and territories and 660 subnational locations, 1950–2023: a demographic analysis for the Global Burden of Disease Study 2023
Abstract
Comprehensive, comparable, and timely estimates of demographic metrics-including life expectancy and age-specific mortality-are essential for evaluating, understanding, and addressing trends in population health. The COVID-19 pandemic highlighted the importance of timely and all-cause mortality estimates for being able to respond to changing trends in health outcomes, showing a strong need for demographic analysis tools that can produce all-cause mortality estimates more rapidly with more readily available all-age vital registration (VR) data. The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) is an ongoing research effort that quantifies human health by estimating a range of epidemiological quantities of interest across time, age, sex, location, cause, and risk. This study-part of the latest GBD release, GBD 2023-aims to provide new and updated estimates of all-cause mortality and life expectancy for 1950 to 2023 using a novel statistical model that accounts for complex correlation structures in demographic data across age and time.
We used 24 025 data sources from VR, sample registration, surveys, censuses, and other sources to estimate all-cause mortality for males, females, and all sexes combined across 25 age groups in 204 countries and territories as well as 660 subnational units in 20 countries and territories, for the years 1950-2023. For the first time, we used complete birth history data for ages 5-14 years, age-specific sibling history data for ages 15-49 years, and age-specific mortality data from Health and Demographic Surveillance Systems. We developed a single statistical model that incorporates both parametric and non-parametric methods, referred to as OneMod, to produce estimates of all-cause mortality for each age-sex-location group. OneMod includes two main steps: a detailed regression analysis with a generalised linear modelling tool that accounts for age-specific covariate effects such as the Socio-demographic Index (SDI) and a population attributable fraction (PAF) for all risk factors combined; and a non-parametric analysis of residuals using a multivariate kernel regression model that smooths across age and time to adaptably follow trends in the data without overfitting. We calibrated asymptotic uncertainty estimates using Pearson residuals to produce 95% uncertainty intervals (UIs) and corresponding 1000 draws. Life expectancy was calculated from age-specific mortality rates with standard demographic methods. For each measure, 95% UIs were calculated with the 25th and 975th ordered values from a 1000-draw posterior distribution.
Citation impact
- FWCI
- 334.67
- Percentile
- 100%
- References
- 38
Authors
2327Topics & keywords
- Life expectancy
- Burden of disease
- Demographic analysis
- Disease burden
- Disease
- Developed country
- Disability-adjusted life year
- Demographic change
Funding
- NSNational Science FoundationAward: 2020-2023
- UDU.S. Department of Veterans Affairs
- BABill and Melinda Gates FoundationAward: OPP1152504
- AHAmerican Heart Association
- GAGAVI Alliance
- AAmgen
- ELEli Lilly and Company
- PPfizer
- AAstraZeneca
- SSanofi
- GFGlobal Fund to Fight AIDS, Tuberculosis and Malaria
- WHWorld Health Organization
- YUYale University
- BBiogen
- TPTeva Pharmaceutical Industries
- AHAlberta Health Services
- UDUniversidade da Beira Interior
- IUInternational Union of Basic and Clinical Pharmacology
- WTWellcome TrustAwards: 2023-24, 220211, 221854, 221854/Z/20/Z, R01AG056477
- IAInternational Association for Suicide Prevention
- SKState Key Laboratory of Respiratory Disease
- SOSociety of Cardiovascular Anesthesiologists
- ACAmarin Corporation
- MDMinisterio de Ciencia, Innovación y UniversidadesAwards: 2024-2026, PID2021-129099OB-I00
- HPHorizon Pharmaceuticals
- FMFresenius Medical Care North America
- EPEsteve Pharmaceuticals
- SMSociedad Madrileña de Nefrología
- MCMinisterul Cercetării, Inovării şi DigitalizăriiAward: 7N/2023
- MModerna
- STSeres Therapeutics
- UOUniversity of Alberta
- NINational Institute for Health and Care Research
- BHBritish Heart Foundation
- DODepartment of Health and Social Care
- HRHeart Research UK
- BPBritish Pharmacological Society
- ECEuropean CommissionAwards: 2023-24, RRF-2.3.1-21-2022-00006, 2022-2027, 221854
- ESEuropean Society of Cardiology
- ICIndian Council of Medical ResearchAward: 2023-24
- MOMinistry of Health, New Zealand
- MOMinistry of Education, Culture, Sports, Science and TechnologyAwards: 24H00663, 2020-2023
- NNNational Natural Science Foundation of ChinaAwards: 202401, 2020-2023, 2024-2026, 72474005, 82303338
- KSKing Saud University
- MDMinistero della SaluteAward: 34/2017
- CNConselho Nacional de Desenvolvimento Científico e TecnológicoAward: 316607/2021-5
- NNNovo Nordisk
- SSanten
- TUTehran University of Medical Sciences and Health Services
- TMTaipei Medical University
- APAstellas Pharma
- NTNational Taiwan Normal University
- UOUniversity of the Philippines
- MUMarga und Walter Boll-Stiftung
- SServier
- TWTempleton World Charity Foundation
- SOSwedish Orphan Biovitrum
- CRCasen Recordati
- HLH. Lundbeck A/S
- UPUniversitat Politècnica de Catalunya
- IItalfarmaco
- NNeuraxpharm
- SPSuicide Prevention Australia
- NSNational Science and Technology Council
- NINational Institutes of HealthAwards: R01AG056477, 2R01AG057531, 2R01AG057531-02A1, 2020-2023, R01AG062553
- MRMedical Research CouncilAwards: MR/Y014154/1, Y014154
- BABiotechnology and Biological Sciences Research Council
- NHNational Health and Medical Research CouncilAwards: APP2009306, APP1169489
- JSJapan Science and Technology AgencyAward: JPMJPR22R8
- NRNational Research, Development and Innovation OfficeAward: RRF-2.3.1-21-2022-00006
- NINorwegian Institute of Public Health
- PRPrecursory Research for Embryonic Science and TechnologyAward: JPMJPR22R8
- DSDaiichi Sankyo Europe